Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Adenosine Deaminase-Severe Combined Immunodeficiency Industry By The Forecast Year 2029?
The adenosine deaminase-severe combined immunodeficiency market has experienced robust expansion in recent years. This market is projected to expand from $5.57 billion in 2024 to $5.94 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.6%. The historical growth can be attributed to several factors, including the increasing prevalence of severe combined immunodeficiency, a rising incidence of PID, a general growth in the prevalence of immunodeficiencies, increased healthcare investments, and heightened awareness of immunodeficiencies.
The adenosine deaminase-severe combined immunodeficiency market is projected to experience robust expansion in the coming years. This market is anticipated to reach $7.64 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by several factors, including the increasing occurrence of genetic disorders, greater utilization of bone marrow transplantation, a surge in demand for non-conditioned stem cell transplantation, the growing incidence of ADA deficiency, and an escalating number of adenosine deaminase deficiency (PDA) cases. Key developments expected during this period encompass technological progress, the embrace of gene therapy, governmental support, sophisticated genetic testing methods, and breakthroughs in biotechnology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21085&type=smp
What Are The Main Drivers Boosting The Adenosine Deaminase-Severe Combined Immunodeficiency Industry’s Expansion?
The anticipated rise in genetic disorders is poised to drive the growth of the adenosine deaminase-severe combined immunodeficiency market in the coming years. Genetic disorders are defined as medical conditions stemming from abnormalities or mutations in an individual’s DNA, which can be either inherited or occur spontaneously. This increasing prevalence of genetic disorders is influenced by factors such as enhanced diagnostic technologies, greater public awareness, an aging parental population, environmental impacts, and population expansion. The growing incidence of genetic disorders, particularly in conditions like adenosine deaminase-severe combined immunodeficiency (ADA-SCID), fuels a heightened demand for advanced diagnostic methods and targeted treatments. For example, a report published by the Department of Health & Social Care (DHSC), a UK-based government department, in December 2022, revealed that as of October 2022, approximately 33,000 whole genome equivalents had been sequenced, yielding an average diagnostic rate of 32%, which escalated to 61% in certain specific conditions. Thus, the escalating prevalence of genetic disorders is fundamentally propelling the expansion of the adenosine deaminase-severe combined immunodeficiency market.
How Is The Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmented?
The adenosine deaminase-severe combined immunodeficiencymarket covered in this report is segmented –
1) By Treatment Type: Enzyme Replacement Therapy (ERT); Gene Therapy; Stem Cell Transplantation; Supportive Care Treatments
2) By Route of Administration: Intravenous; Subcutaneous; Oral
3) By Age Group: Pediatric (Infants and Children); Adults
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Others End-Users
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement; Pegylated Erythropoietin (PEG-EPO)
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy; Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant; Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy; Immune System Support; Nutritional Support
What Key Innovation Trends Are Fueling Advancements In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?
Leading companies within the adenosine deaminase-severe combined immunodeficiency market are prioritizing novel therapeutic approaches, such as gene therapy for rare diseases. Their aim is to enhance treatment results, extend patient survival, and tackle the foundational genetic issues of the disorder using sophisticated medical technologies. Specifically, gene therapy in adenosine deaminase-severe combined immunodeficiency (ADA-SCID) endeavors to rectify the genetic flaw by inserting a working ADA gene copy, potentially offering a lasting remedy for individuals afflicted with this uncommon and severe immune condition. Illustrating this focus, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics innovator, became a member of the Bespoke Gene Therapy Consortium (BGTC), an initiative under the Accelerating Medicines Partnership (AMP) program. Collaborating with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, this consortium strives to advance personalized gene therapies for rare diseases and improve the efficiency of their development. This collaboration is notably significant as it signifies a combined endeavor to overcome the hurdles in conventional drug development for rare diseases—conditions frequently attracting minimal commercial interest because of their infrequent occurrence.
Which Key Players Are Driving Competition In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc, Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, QED Bioscience Inc.
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Adenosine Deaminase-Severe Combined Immunodeficiency Market During The Forecast Period?
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Adenosine Deaminase-Severe Combined Immunodeficiency Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21085&type=smp
Browse Through More Reports Similar to the Global Adenosine Deaminase-Severe Combined Immunodeficiency Market 2025, By The Business Research Company
Enzyme Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Enzyme Replacement Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/enzyme-replacement-therapy-global-market-report
Ligases Enzyme Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ligases-enzyme-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model